Compare Impinj Inc (PI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs TG Therapeutics Inc — how do they compare? Impinj Inc trades at $189.55 (market cap $5.60B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and TG Therapeutics Inc for 16 Days on average.
| PI | TGTX | |
|---|---|---|
Market Cap | $5.60B | $8.16B |
Volume | 9,929 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $241.91 | $59.06 |
52-Week Low | $91.34 | $26.94 |
Typical Hold Time | 22 Days | 16 Days |
Enterprise Value | $5.73B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $183.37, down 4.01% today, with strong analyst support (16 Buy, 0 Sell) and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations ($0.86 vs. $0.795), but the company remains unprofitable with a -7.26% net margin. Technical indicators show a bullish trend, with support at $181 and resistance at $188. The stock is positioned near its pivot point of $185 amid ongoing operational growth in RFID technology.
Outlook: PI offers growth potential in RFID markets, but profitability concerns and high valuations (P/S 14.83, EV/EBITDA 523.68) pose risks. Investors should weigh strong revenue trends against negative margins and monitor Q3 2026 results for sustained execution. Near-term price action may hinge on technical support levels and institutional sentiment.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
